6190 Stock Overview
Provides contract study services for drug discovery and development primarily in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PhoenixBio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥325.00 |
| 52 Week High | JP¥580.00 |
| 52 Week Low | JP¥320.00 |
| Beta | 0.34 |
| 1 Month Change | -11.92% |
| 3 Month Change | -26.64% |
| 1 Year Change | -29.65% |
| 3 Year Change | -36.02% |
| 5 Year Change | -60.80% |
| Change since IPO | -88.60% |
Recent News & Updates
Shareholder Returns
| 6190 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -3.0% | 0.6% | 0.5% |
| 1Y | -29.7% | -11.1% | 13.6% |
Return vs Industry: 6190 underperformed the JP Life Sciences industry which returned -11.1% over the past year.
Return vs Market: 6190 underperformed the JP Market which returned 13.6% over the past year.
Price Volatility
| 6190 volatility | |
|---|---|
| 6190 Average Weekly Movement | 4.5% |
| Life Sciences Industry Average Movement | 5.6% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 6190 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 6190's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 70 | Takashi Shimada | www.phoenixbio.co.jp |
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations.
PhoenixBio Co., Ltd. Fundamentals Summary
| 6190 fundamental statistics | |
|---|---|
| Market cap | JP¥1.32b |
| Earnings (TTM) | -JP¥125.00m |
| Revenue (TTM) | JP¥1.62b |
0.8x
P/S Ratio-10.5x
P/E RatioIs 6190 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6190 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.62b |
| Cost of Revenue | JP¥451.00m |
| Gross Profit | JP¥1.17b |
| Other Expenses | JP¥1.30b |
| Earnings | -JP¥125.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -30.86 |
| Gross Margin | 72.19% |
| Net Profit Margin | -7.71% |
| Debt/Equity Ratio | 26.1% |
How did 6190 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:21 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PhoenixBio Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|